

<b>INFORMATION DISCLOSURE STATEMENT</b> <small>(37 CFR 1.56, 1.97, and 1.98)</small>				ATTORNEY DOCKET 25352-0029	APPLICATION NO. 09/977,059	
				APPLICANT(S) Prasad V.V.S.V. Manchem et al.		
				FILING DATE October 11, 2001	ART UNIT 1617	
<b>U.S. PATENT DOCUMENTS</b>						
† EX'R INITIAL	* REF. #	PATENT NUMBER	DATE (MO/YR)	NAME	CLASS/ SUBCLASS	FILING DATE (If appropriate)

**FOREIGN PATENT DOCUMENTS**

† EX'R INITIAL	* REF. #	COUNTRY	PATENT NUMBER	DATE (MO/YR)	APPLICANT	TRANSLATION

**OTHER DOCUMENTS**

† EX'R INITIAL	* REF. #	CITATION (Author, Article Title, Journal/Book Title, Date, Pertinent Pages, etc.)			
MP	19	Schütt et al., "The HIV-1 protease inhibitor indinavir impairs insulin signalling in HepG2 hepatoma cells", <i>Diabetologia</i> , 43, 1145-1148 (2000)			
	20	Saint-Marc et al., "Effects of metformin on insulin resistance and central adiposity in patients receiving effective protease inhibitor therapy", <i>AIDS</i> , 13(8), 1000-1002 (1999).			
	21	"AACTG recommendations for metabolic problems", <i>AIDS ALERT</i> , p.6 (January 2003)			
NP	22.	Tanwani et al., "Lipodystrophy, insulin resistance, diabetes mellitus, dyslipidemia, and cardiovascular disease in human immunodeficiency virus infection", <i>Southern Medical Journal</i> , 96(2), 180-188 (2003)			

EXAMINER'S SIGNATURE <i>Myic S</i>	DATE CONSIDERED 06/10/03
† EXAMINER: Initial if reference is considered, whether or not citation is in conformance with MPEP 609. Line through citation if not in conformance and not considered. <i>Include copy of this form in next communication to applicant.</i>	
* If an asterisk is placed beside the reference number, a copy is not provided because the reference was previously cited by or submitted to the PTO in a prior application that is identified in the statement and relied upon for an earlier filing date under 35 U.S.C. 120. 37 C.F.R. 1.98(d).	